Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Recommendation of “Moderate Buy” from Analysts

Vor Biopharma Inc. (NASDAQ:VOR) has received an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $76.50.

Several equities research analysts have commented on VOR shares. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Wednesday, September 24th. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 15th. HC Wainwright increased their price objective on Vor Biopharma to $52.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Zacks Research upgraded Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th.

Vor Biopharma Trading Down 3.1%

VOR opened at $9.75 on Friday. The firm’s fifty day moving average is $29.53. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The stock has a market capitalization of $66.79 million, a P/E ratio of -0.04 and a beta of 2.02.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Thursday, November 13th. The company reported ($3.33) EPS for the quarter, missing analysts’ consensus estimates of ($3.06) by ($0.27).

Insider Transactions at Vor Biopharma

In related news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $1.54, for a total transaction of $688,808.12. Following the completion of the sale, the insider owned 32,781,209 shares of the company’s stock, valued at approximately $50,483,061.86. This represents a 1.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ra Capital Management, L.P. sold 260,859 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $29.39, for a total transaction of $7,666,646.01. Following the completion of the sale, the director owned 15,104 shares of the company’s stock, valued at approximately $443,906.56. The trade was a 94.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,431,718 shares of company stock worth $62,090,254 over the last 90 days. 0.45% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in Vor Biopharma in the first quarter worth approximately $140,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma in the 1st quarter valued at $100,000. Ariose Capital Management Ltd acquired a new position in shares of Vor Biopharma in the 3rd quarter valued at $5,368,000. Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the 2nd quarter worth about $66,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.